PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Case Study

Volume 4 Issue 3

Case Study concerning Ulcerative Colitis with Literature Review

Christina Rahm*

August 16, 2024

DOI : 10.56831/PSSRP-04-131

View PDF

Abstract

According to Zhu et al. (2021), Medicine and Health encloses the study of the prevention, care, and tendering of diseases as well as the examination of physical and mental well-being. Medicines can help control things like high blood pressure or high cholesterol. These drugs cannot cure the hidden problems, but they can help prevent some of its body damaging effects overtime among important medicines are immunization. A lot of medicines are swallowed, either as pills or a liquid. Once the medicine is swallowed, the digestive juice in the stomach breaks it down, and the medicine can progress into the bloodstream. Blood then carries it to other parts of your body where the medicines work best.

References

  1. Armuzzi A and Liguori G. “Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review”. Digestive and Liver Disease 53.7 (2021): 803-808.
  2. Alsoud D., et al. “Breaking the therapeutic ceiling in drug development in ulcerative colitis”. Lancet Gastroenterol Hepatol 6.7 (2021): 589-595.
  3. Dolin J. “The special Nordic science education and science education research tradition– and the importance of nursing it”. Science Education in the light of Global Sustainable Development:-trends and possibilities 15 (2021).
  4. Feagan BG., et al. “Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial”. The Lancet 397.10292 (2021).
  5. Gottlieb K., et al. “Central reading of ulcerative colitis clinical trial videos using neural networks”. Gastroenterology 160.3 (2021): 710-719.
  6. Kucharzik T., et al. “Ulcerative colitis—diagnostic and therapeutic algorithms”. Deutsches Ärzteblatt International 117.33-34 (2020): 564-574.
  7. Lai K and Fujinami T. “A Comparative Study on the Expectation of Active Seniors in Nursing Care between Japan and China”. In 2021 5th International Conference on Medical and Health Informatics (2021): 259-264.
  8. Naftali T., et al. “Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial”. PloS one 16.2 (2021): e0246871.
  9. Sandborn WJ., et al. “Ozanimod as induction and maintenance therapy for ulcerative colitis”. New England Journal of Medicine 385.14 (2021): 1280-1291.
  10. Sands BE., et al. “Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis”. New England Journal of Medicine 381.13 (2019): 1215-1226.
  11. Smillie CS., et al. “Intra-and inter-cellular rewiring of the human colon during ulcerative colitis”. Cell 178.3 (2019): 714-730.
  12. Spinelli A., et al. “ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment”. Journal of Crohn's and Colitis 16.2 (2022): 179-189.
  13. Tripathi K and Feuerstein JD. “New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance”. Drugs in context 8 (2019).
  14. Ungaro R., et al. “A treat-to-target update in ulcerative colitis: a systematic review”. The American journal of gastroenterology 114.6 (2019): 874-883.
  15. Zakerska-Banaszak O., et al. “Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: A pilot study”. Scientific reports 11.1 (2021).
  16. Zhu Y., et al. “CXCL8 chemokine in ulcerative colitis”. Biomedicine & Pharmacotherapy 138 (2021): 111427.